XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.3

Revenue (Tables)

9 Months Ended

Sep. 30, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following table summarizes our revenue recognized in our consolidated condensed statements of operations:

			Three Months Ended September 30,												Nine Months Ended September 30,
			2024						2023						2024						2023
Net product revenue			$	10,571.6					$	7,306.2					$	28,723.0					$	20,524.2
Collaboration and other revenue			867.5						2,192.4						2,786.9						4,246.5
Revenue			$	11,439.1					$	9,498.6					$	31,509.9					$	24,770.7

The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the three months ended September 30, 2024 and 2023:

			Three Months Ended September 30,
			2024												2023
			U.S.			Outside U.S.			Total						U.S.			Outside U.S.			Total
Cardiometabolic Health:
Mounjaro®			$	2,384.7		$	728.0		$	3,112.7					$	1,277.0		$	132.4		$	1,409.3
Trulicity®			935.3			366.0			1,301.4						1,259.0			414.6			1,673.6
Zepbound®			1,257.8			—			1,257.8						—			—			—
Jardiance(1)			335.9			350.5			686.4						415.9			284.8			700.8
Humalog® (2)			323.9			210.8			534.6						194.2			201.2			395.4
Humulin®			149.9			57.1			207.1						145.5			61.2			206.7
Basaglar® (3)			85.5			76.2			161.6						111.4			68.2			179.6
Baqsimi			8.2			5.1			13.4						3.8			9.3			13.1
Other cardiometabolic health			35.8			96.3			132.0						53.2			88.6			141.9
Total cardiometabolic health			5,517.0			1,890.0			7,407.0						3,460.0			1,260.3			4,720.4
Oncology:
Verzenio®			878.8			490.4			1,369.3						684.6			355.7			1,040.2
Cyramza®			106.5			129.4			236.0						88.0			136.1			224.1
Erbitux®			133.2			18.7			152.0						134.0			19.9			153.9
Tyvyt®			—			150.2			150.2						—			115.1			115.1
Other oncology			175.8			148.8			324.3						95.0			118.7			213.8
Total oncology			1,294.3			937.5			2,231.8						1,001.6			745.5			1,747.1
Immunology:
Taltz®			600.3			279.3			879.6						509.3			234.9			744.2
Olumiant®			68.9			181.8			250.8						65.7			165.7			231.4
Other immunology			24.9			30.5			55.3						—			11.4			11.4
Total immunology			694.1			491.6			1,185.7						575.0			412.0			986.9
Neuroscience:
Emgality®			141.3			61.6			202.9						126.5			42.1			168.5
Zyprexa (4)			1.9			29.8			31.7						49.9			1,431.5			1,481.4
Other neuroscience			58.1			59.1			117.2						31.0			87.0			118.2
Total neuroscience			201.3			150.5			351.8						207.4			1,560.6			1,768.1
Other:
Forteo®			71.7			46.4			118.1						101.2			45.2			146.4
Cialis®			4.2			87.3			91.5						4.9			82.0			86.8
Other			31.1			22.1			53.2						18.0			24.8			42.9
Total other			107.0			155.8			262.8						124.1			152.0			276.1
Revenue			$	7,813.6		$	3,625.5		$	11,439.1					$	5,368.1		$	4,130.5		$	9,498.6

Numbers may not add due to rounding.

(1) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.

(2) Humalog revenue includes insulin lispro.

(3) Basaglar revenue includes Rezvoglar®.

(4) Zyprexa revenue includes sale of rights for the olanzapine portfolio in July 2023.

The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the nine months ended September 30, 2024 and 2023:

			Nine Months Ended September 30,
			2024												2023
			U.S.			Outside U.S.			Total						U.S.			Outside U.S.			Total
Cardiometabolic Health:
Mounjaro			$	6,318.7		$	1,691.3		$	8,010.0					$	2,729.1		$	228.4		$	2,957.5
Trulicity			2,894.0			1,109.3			4,003.3						4,177.7			1,285.6			5,463.2
Zepbound			3,018.4			—			3,018.4						—			—			—
Jardiance(1)			1,133.1			1,009.4			2,142.5						1,131.5			815.1			1,946.6
Humalog(2)			1,096.8			608.1			1,704.9						695.6			601.2			1,296.8
Humulin			472.3			164.5			636.8						488.6			175.4			664.0
Basaglar(3)			273.9			226.1			500.0						329.7			213.4			543.1
Baqsimi			1.4			23.4			24.8						633.1			25.4			658.4
Other cardiometabolic health			114.4			259.5			373.9						131.1			260.7			392.0
Total cardiometabolic health			15,323.0			5,091.6			20,414.6						10,316.4			3,605.2			13,921.6
Oncology:
Verzenio			2,378.4			1,373.1			3,751.5						1,734.2			983.7			2,717.9
Cyramza			329.9			384.8			714.7						303.6			417.5			721.1
Erbitux			408.2			44.2			452.4						398.3			48.0			446.3
Tyvyt			—			389.9			389.9						—			279.7			279.7
Other oncology			451.4			440.6			892.0						253.9			355.2			609.1
Total oncology			3,567.9			2,632.6			6,200.5						2,690.0			2,084.1			4,774.1
Immunology:
Taltz			1,486.7			821.7			2,308.4						1,293.8			681.2			1,975.0
Olumiant			159.8			536.0			695.9						158.8			520.4			679.2
Other immunology			44.5			53.3			97.7						—			39.0			39.0
Total immunology			1,691.0			1,411.0			3,102.0						1,452.6			1,240.6			2,693.2
Neuroscience:
Emgality			404.0			216.7			620.6						354.0			138.2			492.2
Zyprexa (4)			0.5			107.0			107.5						69.1			1,581.9			1,651.0
Other neuroscience			151.9			200.3			352.3						89.7			282.9			372.6
Total neuroscience			556.4			524.0			1,080.4						512.8			2,003.0			2,515.8
Other:
Cialis			17.6			301.0			318.6						21.6			281.1			302.7
Forteo			124.9			124.4			249.3						269.2			147.6			416.8
Other			62.5			82.0			144.5						73.0			73.4			146.5
Total other			205.0			507.4			712.4						363.8			502.1			866.0
Revenue			$	21,343.2		$	10,166.7		$	31,509.9					$	15,335.6		$	9,435.0		$	24,770.7

Numbers may not add due to rounding.

(1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.

(2) Humalog revenue includes insulin lispro.

(3) Basaglar revenue includes Rezvoglar.

(4) Zyprexa revenue includes sale of rights for the olanzapine portfolio in July 2023.

The following table summarizes revenue by geographical area:

			Three Months Ended September 30,												Nine Months Ended September 30,
			2024						2023						2024						2023
Revenue(1):
U.S.			$	7,813.6					$	5,368.1					$	21,343.2					$	15,335.6
Europe			1,628.3						2,568.6						4,472.7						4,837.1
Japan			429.1						390.8						1,255.7						1,233.6
China			459.9						390.8						1,231.2						1,162.6
Other foreign countries			1,108.2						780.3						3,207.1						2,201.8
Revenue			$	11,439.1					$	9,498.6					$	31,509.9					$	24,770.7

Numbers may not add due to rounding.

(1) Revenue is attributed to the countries based on the location of the customer or other party.

Schedule of Amounts Recorded for Contract Liabilities

The following table summarizes contract liability balances:

			September 30, 2024						December 31, 2023
Contract liabilities			$	173.2					$	193.6

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration